CoChat

Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients—a multinational observational study by the European Confederation of Medical Mycology

Open access
Prattes, Juergen, Wauters, Joost, Giacobbe, Daniele Roberto, Salmanton-García, Jon, Maertens, Johan, Bourgeois, Marc, Reynders, Marijke, Rutsaert, Lynn, Van Regenmortel, Niels, Lormans, Piet, Feys, Simon, Reisinger, Alexander Christian, Cornely, Oliver A., Lahmer, Tobias, Valerio, Maricela, Delhaes, Laurence, Jabeen, Kauser, Steinmann, Joerg, Chamula, Mathilde, Bassetti, Matteo, Hatzl, Stefan, Rautemaa-Richardson, Riina, Koehler, Philipp, Lagrou, Katrien, Hoenigl, Martin, Debaveye, Yves, Miceli, Marisa H., Tudesq, Jean-Jacques, Paul, Gregor, Krause, Robert, Linhofer, Marina, Frost, Jonas, Zechner, Peter, Kochanek, Matthias, Eller, Philipp, Jenks, Jeffrey D., Volpi, Sara, Bellanger, Anne-Pauline, White, P.Lewis, Goldman, Gustavo H., Bowyer, Paul, Rokas, Antonis, Gago, Sara, Pelosi, Paolo, Robba, Chiara, Gangneux, Jean-Pierre, Lass-Floerl, Cornelia, Machado, Marina, Muñoz, Patricia · 2022 · Clinical Microbiology and Infection
Cited by 233

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Objectives Coronavirus disease 2019 (COVID-19) -associated pulmonary aspergillosis (CAPA) has emerged as a complication in critically ill COVID-19 patients. The objectives of this multinational study were to determine the prevalence of CAPA in patients with COVID-19 in intensive care units (ICU) and to investigate risk factors for CAPA as well as outcome. Methods The European Confederation of Medical Mycology (ECMM) conducted a multinational study including 20 centres from nine countries to assess epidemiology, risk factors and outcome of CAPA. CAPA was defined according to the 2020 ECMM/ISHAM consensus definitions. Results A total of 592 patients were included in this study, including 11 (1.9%) patients with histologically proven CAPA, 80 (13.5%) with probable CAPA, 18 (3%) with possible CAPA and 483 (81.6%) without CAPA. CAPA was diagnosed a median of 8 days (range 0–31 days) after ICU admission predominantly in older patients (adjusted hazard ratio (aHR) 1.04 per year; 95% CI 1.02–1.06) with any form of invasive respiratory support (HR 3.4; 95% CI 1.84–6.25) and receiving tocilizumab (HR 2.45; 95% CI 1.41–4.25). Median prevalence of CAPA per centre was 10.7% (range 1.7%–26.8%). CAPA was associated with significantly lower 90-day ICU survival rate (29% in patients with CAPA versus 57% in patients without CAPA; Mantel–Byar p < 0.001) and remained an independent negative prognostic variable after adjusting for other predictors of survival (HR 2.14; 95% CI 1.59–2.87, p ≤ 0.001). Conclusion Prevalence of CAPA varied between centres. CAPA was significantly more prevalent among older patients, patients receiving invasive ventilation and patients receiving tocilizumab, and was an independent strong predictor of ICU mortality.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cmi.2021.08.014

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 233

Metadata

Authors
Prattes, J., Wauters, J., Giacobbe, D. R., Salmanton-García, J., Maertens, J., Bourgeois, M., Reynders, M., Rutsaert, L., Van Regenmortel, N., Lormans, P., Feys, S., Reisinger, A. C., Cornely, O. A., Lahmer, T., Valerio, M., Delhaes, L., Jabeen, K., Steinmann, J., Chamula, M., Bassetti, M., Hatzl, S., Rautemaa-Richardson, R., Koehler, P., Lagrou, K., Hoenigl, M., Debaveye, Y., Miceli, M. H., Tudesq, J.-J., Paul, G., Krause, R., Linhofer, M., Frost, J., Zechner, P., Kochanek, M., Eller, P., Jenks, J. D., Volpi, S., Bellanger, A.-P., White, P. L., Goldman, G. H., Bowyer, P., Rokas, A., Gago, S., Pelosi, P., Robba, C., Gangneux, J.-P., Lass-Floerl, C., Machado, M., & Muñoz, P.
Venue
Clinical Microbiology and Infection
Publisher
Elsevier BV
Published
2022-04
Volume
28
Issue
4
Pages
580-587
ISSN
1198-743X (ISSN-L)
OpenAlex
W3193623972
Cited by
233
References
32
FWCI
13.03
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.